{
    "data": [
        {
            "id": "69a18a1d24c37e0001bbe6cd",
            "title": "Equinix, CPP Bet $4 Billion On Nordic AI Boom With atNorth Deal",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Canada Pension Plan Investment Board </strong>(CPP Investments) and <strong>Equinix Inc. </strong><a href=\"https://www.benzinga.com/quote/EQIX\" rel=\"noreferrer noopener\" target=\"_blank\"></a><a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"EQIX\" href=\"https://www.benzinga.com/quote/EQIX\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/EQIX\" target=\"_blank\">EQIX</a>)<!-- --> announced Friday a <a href=\"https://www.benzinga.com/pressreleases/26/02/n50919791/cpp-investments-and-equinix-to-acquire-atnorth-for-us-4-billion\" rel=\"noreferrer noopener\" target=\"_blank\">joint agreement to acquire</a><strong> atNorth</strong>, a leading Nordic data center operator, from<strong> Partners Group </strong><a href=\"https://www.benzinga.com/quote/PGPHF\" rel=\"noreferrer noopener\" target=\"_blank\"></a><a class=\"ticker-link\" data-exchange=\"OTC\" data-ticker=\"PGPHF\" href=\"https://www.benzinga.com/quote/PGPHF\" rel=\"noopener\" target=\"_blank\">(OTC:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/PGPHF\" target=\"_blank\">PGPHF</a>)<!-- --> in a transaction valued at approximately $4 billion, subject to regulatory approvals and customary closing conditions.</p><!--/$--><!--$--><p class=\"block core-block\">The partners outlined a provisional $4.2 billion (3.6 billion euros) financing package to fund the acquisition and future expansion.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Deal Snapshot</h2><!--/$--><!--$--><p class=\"block core-block\">CPP Investments will invest roughly $1.6 billion for an estimated 60% controlling stake, while Equinix will hold the remaining 40%. Equinix expects the acquisition to be immediately accretive to its adjusted funds from operations per share upon closing.</p><!--/$--><!--$--><p class=\"block core-block\">atNorth operates eight data centers across Denmark, Finland, Iceland, Norway, and Sweden, with additional sites under development. The company has secured approximately 1 gigawatt of power capacity and maintains an installed and active development pipeline of around 800 megawatts expected to come online over the next five years. Several facilities are equipped with liquid cooling systems to support high-density AI and high-performance computing workloads.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Why The Nordics</h2><!--/$--><!--$--><p class=\"block core-block\">The companies highlighted the Nordics as an increasingly attractive region for large-scale computing due to strong technical talent, resilient economies, access to renewable energy, and cooler climates.</p><!--/$--><!--$--><p class=\"block core-block\">“The scalable sites of atNorth are very complementary to Equinix’s connectivity services and global footprint. Combined with our joint focus on sustainability, this acquisition is expected to enhance our ability to help customers unlock the full potential of the Nordics’ expanding digital landscape,” said<strong> Bruce Owen</strong>, President, EMEA, Equinix.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">“For businesses looking to scale with resilience, Equinix offers a future-ready infrastructure for long-term success, maintaining the jurisdictional and data sovereignty of organizations operating in the region,” Owen added.</p><!--/$--><!--$--><p class=\"block core-block\">atNorth CEO <strong>Eyjólfur Magnús Kristinsson</strong> called the deal “a powerful validation of atNorth’s journey and its market position as the leading Nordics data center platform,” adding that it is expected to enhance access to capital and deepen hyperscale relationships. The company will continue to operate under the atNorth brand.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>EQIX Price Action:</strong> Equinix shares were unchanged at $948.02 during premarket trading on Friday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by JHVEPhoto via Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50923232\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Equinix-Silicon-Valley-Office-Building-I.jpeg",
            "link": "https://www.benzinga.com/m-a/26/02/50923232/equinix-cpp-bet-4-billion-on-nordic-ai-boom-with-atnorth-deal",
            "pub_date": "2026-02-27 20:12:16",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a18adb24c37e0001bbe6ef",
            "title": "This Brown &amp; Brown Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href=\"https://www.benzinga.com/analyst-stock-ratings\" target=\"_blank\">analyst ratings page</a>.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Considering buying BRO stock? Here’s what analysts think: </p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50923265\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/27/Mobile-Phone-Displaying-Block--Inc--Logo.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/upgrades/26/02/50923265/this-brown-here-are-top-5-upgrades-for-friday",
            "pub_date": "2026-02-27 20:15:26",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1889424c37e0001bbe5e9",
            "title": "12 Health Care Stocks Moving In Friday&#39;s Pre-Market Session",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><h3 class=\"block core-block\">Gainers</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li><strong>Ensysce Biosciences</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ENSC\" target=\"_blank\">ENSC</a>) shares rose 40.4% to $0.55 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 million. </li>\n<li><strong>Cardio Diagnostics Hldgs</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CDIO\" target=\"_blank\">CDIO</a>) stock rose 23.18% to $6.43. The market value of their outstanding shares is at $9.5 million. </li>\n<li><strong>Neurogene</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NGNE\" target=\"_blank\">NGNE</a>) shares rose 20.93% to $23.8. The company's market cap stands at $304.8 million. </li>\n<li><strong>Caris Life Sciences</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CAI\" target=\"_blank\">CAI</a>) stock increased by 14.81% to $22.09. The market value of their outstanding shares is at $5.4 billion. As per the press release, Q4 earnings came out yesterday. </li>\n<li><strong>BioAtla</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/BCAB\" target=\"_blank\">BCAB</a>) shares moved upwards by 10.78% to $0.26. The market value of their outstanding shares is at $17.6 million. </li>\n<li><strong>Candel Therapeutics</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CADL\" target=\"_blank\">CADL</a>) stock increased by 8.73% to $5.6. The company's market cap stands at $282.7 million. </li>\n</ul><!--/$--><!--$--><h3 class=\"block core-block\">Losers</h3><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/movers_1.jpg",
            "link": "https://www.benzinga.com/insights/movers/26/02/50923004/12-health-care-stocks-moving-in-fridays-pre-market-session",
            "pub_date": "2026-02-27 20:05:45",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1889a24c37e0001bbe5f2",
            "title": "12 Consumer Discretionary Stocks Moving In Friday&#39;s Pre-Market Session",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><h3 class=\"block core-block\">Gainers</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li><strong>707 Cayman Holdings</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/JEM\" target=\"_blank\">JEM</a>) stock rose 22.2% to $0.11 during Friday's pre-market session. The market value of their outstanding shares is at $1.7 million. </li>\n<li><strong>RealReal</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/REAL\" target=\"_blank\">REAL</a>) shares rose 10.57% to $13.7. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out yesterday. </li>\n<li><strong>Kandal M Venture</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FMFC\" target=\"_blank\">FMFC</a>) stock rose 8.13% to $0.47. The company's market cap stands at $7.9 million. </li>\n<li><strong>FIGS</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FIGS\" target=\"_blank\">FIGS</a>) shares increased by 6.65% to $13.3. The company's market cap stands at $2.0 billion. The company's, Q4 earnings came out yesterday. </li>\n<li><strong>Robo.ai</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AIIO\" target=\"_blank\">AIIO</a>) shares rose 5.91% to $0.13. The company's market cap stands at $42.2 million. </li>\n<li><strong>Mixed Martial Arts Group</strong> (AMEX:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MMA\" target=\"_blank\">MMA</a>) stock moved upwards by 5.01% to $0.58. The market value of their outstanding shares is at $14.6 million. </li>\n</ul><!--/$--><!--$--><h3 class=\"block core-block\">Losers</h3><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/movers_1.jpg",
            "link": "https://www.benzinga.com/insights/movers/26/02/50923013/12-consumer-discretionary-stocks-moving-in-fridays-pre-market-session",
            "pub_date": "2026-02-27 20:05:49",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a1877224c37e0001bbe49b",
            "title": "Demystifying Solventum: Insights From 5 Analyst Reviews",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">In the latest quarter, 5 analysts provided ratings for Solventum (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/SOLV\" target=\"_blank\">SOLV</a>), showcasing a mix of bullish and bearish perspectives.</p><!--/$--><!--$--><p class=\"block core-block\">The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $100.4, a high estimate of $105.00, and a low estimate of $97.00. This upward trend is apparent, with the current average reflecting a 10.33% increase from the previous average price target of $91.00.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Analyzing Analyst Ratings: A Detailed Breakdown</h2><!--/$--><!--$--><p class=\"block core-block\">The analysis of recent analyst actions sheds light on the perception of Solventum by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To gain a panoramic view of Solventum's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/SOLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on Solventum analyst ratings.</strong></a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Unveiling the Story Behind Solventum</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><h3 class=\"block core-block\">Solventum: A Financial Overview</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Solventum's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>0.67%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Solventum's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>60.4%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> Solventum's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>29.34%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Solventum's ROA excels beyond industry benchmarks, reaching <strong>8.72%</strong>. This signifies efficient management of assets and strong financial health.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Solventum's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.03</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">The Significance of Analyst Ratings Explained</h2><!--/$--><!--$--><p class=\"block core-block\">Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p><!--/$--><!--$--><p class=\"block core-block\">In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_5.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50922669/demystifying-solventum-insights-from-5-analyst-reviews",
            "pub_date": "2026-02-27 20:00:55",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}